KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsBuildingsCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressCurrent AssetsCurrent TaxesDividends payablesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtOther Accumulated ExpensesPayablesPensionPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Abbott Laboratories (ABT) Raw Materials (2016 - 2025)

Abbott Laboratories' Raw Materials history spans 17 years, with the latest figure at $1.6 billion for Q4 2025.

  • For Q4 2025, Raw Materials fell 2.78% year-over-year to $1.6 billion; the TTM value through Dec 2025 reached $1.6 billion, down 2.78%, while the annual FY2025 figure was $1.6 billion, 2.78% down from the prior year.
  • Raw Materials for Q4 2025 was $1.6 billion at Abbott Laboratories, down from $1.6 billion in the prior quarter.
  • Across five years, Raw Materials topped out at $2.0 billion in Q2 2023 and bottomed at $1.4 billion in Q4 2021.
  • The 5-year median for Raw Materials is $1.7 billion (2024), against an average of $1.7 billion.
  • The largest annual shift saw Raw Materials rose 29.17% in 2021 before it fell 10.73% in 2025.
  • A 5-year view of Raw Materials shows it stood at $1.4 billion in 2021, then grew by 22.14% to $1.7 billion in 2022, then grew by 7.64% to $1.8 billion in 2023, then dropped by 8.97% to $1.7 billion in 2024, then decreased by 2.78% to $1.6 billion in 2025.
  • Per Business Quant, the three most recent readings for ABT's Raw Materials are $1.6 billion (Q4 2025), $1.6 billion (Q3 2025), and $1.7 billion (Q2 2025).